Abstract

Neisseria meningitidis PglL belongs to a novel family of bacterial oligosaccharyltransferases (OTases) responsible for O-glycosylation of type IV pilins. Although members of this family are widespread among pathogenic bacteria, there is little known about their mechanism. Understanding the O-glycosylation process may uncover potential targets for therapeutic intervention, and can open new avenues for the exploitation of these pathways for biotechnological purposes. In this work, we demonstrate that PglL is able to transfer virtually any glycan from the undecaprenyl pyrophosphate (UndPP) carrier to pilin in engineered Escherichia coli and Salmonella cells. Surprisingly, PglL was also able to interfere with the peptidoglycan biosynthetic machinery and transfer peptidoglycan subunits to pilin. This represents a previously unknown post-translational modification in bacteria. Given the wide range of glycans transferred by PglL, we reasoned that substrate specificity of PglL lies in the lipid carrier. To test this hypothesis we developed an in vitro glycosylation system that employed purified PglL, pilin, and the lipid farnesyl pyrophosphate (FarPP) carrying a pentasaccharide that had been synthesized by successive chemical and enzymatic steps. Although FarPP has different stereochemistry and a significantly shorter aliphatic chain than the natural lipid substrate, the pentasaccharide was still transferred to pilin in our system. We propose that the primary roles of the lipid carrier during O-glycosylation are the translocation of the glycan into the periplasm, and the positioning of the pyrophosphate linker and glycan adjacent to PglL. The unique characteristics of PglL make this enzyme a promising tool for glycoengineering novel glycan-based vaccines and therapeutics.

Highlights

  • Carbohydrate Science (AICCS), the Natural Sciences and Engineering Research Council (NSERC), the Canada Foundation for Innovation (CFI), the University of Alberta, the Alberta Ingenuity Fund, and the Alberta Heritage Foundation for Medical Research (AHFMR)

  • We took advantage of the availability of well-defined undecaprenyl pyrophosphate (UndPP)-linked glycans naturally used in LPS and capsule biosynthesis, which can be produced in E. coli, to demonstrate that PglL can transfer virtually any glycan to pilin in vivo

  • PglL Can Transfer Polysaccharides Containing ␤-(134) and ␣-(136) Sugars Linked to the Residue at Position 1—We have previously shown that PglL is able to transfer the C. jejuni heptasaccharide and E. coli O7 antigen from the UndPP carrier to pilin in engineered E. coli cells [6]

Read more

Summary

The abbreviations used are

UndPP, undecaprenyl pyrophosphate; DATDH, 2,4-diacetamido-2,4,6-trideoxyhexose; FarPP, farnesyl pyrophosphate; LLO, lipid-linked oligosaccharide; OTase, oligosaccharyltransferase; PG, peptidoglycan; ProK, proteinase K; LPS, lipopolysaccharide; IPTG, isopropyl-1-thio-␤-D-galactopyranoside; Amp, ampicillin; Cm, chloramphenicol; Gm, gentamycin; Km, kanamycin; Sp, spectinomycin; Strep, streptomycin; Tet, tetracycline; Tp, trimethoprim. We took advantage of the availability of well-defined UndPP-linked glycans naturally used in LPS and capsule biosynthesis, which can be produced in E. coli, to demonstrate that PglL can transfer virtually any glycan to pilin in vivo. This finding prompted us to hypothesize that PglL substrate specificity is located in the lipid carrier. To test this hypothesis, we established an in vitro pilin O-glycosylation assay using a synthetic lipid-linked glycan obtained through successive chemical and enzymatic steps. Our results allowed us to map the region of the substrate recognized by PglL to a very short part of the molecule located at the interface between the glycan and lipid moieties

EXPERIMENTAL PROCEDURES
E69 CWG281
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call